XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Equity (Tables)
9 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Common Stock Reserved for Issuance
The Company has shares of common stock reserved for issuance as follows (in thousands):
December 31, 2022
Common stock warrants641 
2010 Plan
Options outstanding21,223 
2021 Plan
Awards outstanding
2,022 
Shares available for future grant30,945 
2021 ESPP6,321 
Options outstanding outside the plans2,655 
Total63,807 
Stock Option Activity
Stock option activities within the Plans as well as outside of the Plans were as follows:
Number of Shares
(in thousands)
Weighted-Average
Exercise Price
Average Remaining Contractual Term
(in years)
Aggregate Intrinsic Value (in thousands)
Balance, March 31, 202226,983 $4.15 7.63$1,293,545 
Options exercised(2,659)2.77 
Options forfeited or expired(446)5.62 
Balance, December 31, 202223,878 4.27 6.95699,367 
Vested and exercisable as of December 31, 202211,697 2.35 5.97365,043 
Vested and expected to vest as of December 31, 202222,476 4.19 6.89660,023 
Stock Options Valuation Assumptions
The fair value of each option on the date of grant was determined using the Black-Scholes option-pricing model with the assumptions set forth in the following table:
Nine Months Ended December 31, 2021
Fair value of common stock
$18.41 - $21.41
Volatility
46.5% - 47.0%
Risk-free interest rate
0.77% - 1.02%
Expected term (in years)
5.00 - 6.09
Expected dividend
—%
Restricted Stock Unit Activity
The following table summarizes RSU activity (in thousands, except per share information):
Number of SharesWeighted-
Average
Grant Date Fair Value
Unvested balance, March 31, 2022534 $68.23 
Granted1,590 33.91 
Vested(203)54.44 
Forfeited(92)46.55 
Unvested balance, December 31, 20221,829 41.01 
Stock-Based Compensation Expense
Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended December 31,Nine Months Ended December 31,
2022202120222021
Cost of revenue$2,695 $1,912 $7,209 $2,973 
Research and development4,002 2,035 9,416 4,864 
Sales and marketing4,856 2,681 11,912 5,575 
General and administrative2,431 3,206 6,306 8,221 
Total stock-based compensation expense$13,984 $9,834 $34,843 $21,633